Join Us

2022

2021

2020

Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits

IRVINE, Calif. June 1, 2022--Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) announced that the Company had received CE mark approval for three self-developed next generation sequencing (NGS) kits, namely, “OncoScreen™ Plus Cancer Mutation...

Burning Rock Secures Second NGS Kit Approval from the NMPA

GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that the National Medical Products Administration (NMPA) approved Burning Rock’s Human Nine-Gene Mutation Joint Detection...